Single IRB model will 'dramatically accelerate' treatment delivery, says NIH

By Melissa Fassbender contact

- Last updated on GMT

NIH makes progress on single IRB model

Related tags: Institutional review board

The National Institutes of Health (NIH) has reached a milestone in its goal of accelerating multisite clinical studies through a single institutional review board (IRB) model.

NIH’s National Center for Advancing Translational Sciences (NCATS) announced that all Clinical and Translational Science Awards (CTSA) Program sites have signed on to the NCATS Streamlined, Multisite, Accelerated Resources for Trials (SMART) IRB authorization agreement.

The NCATS SMART IRB authorization agreement was developed to establish a harmonized approach for roles and responsibilities of the single IRB and the participating sites​,” Michelle Culp, M.P.H., Director of Clinical Operations, Division of Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, told Outsourcing-Pharma.com.

Enabling all participating sites in a clinical study to rely on the ethics review of a single IRB will streamline the ethics review process, making it possible to initiate multisite studies faster​,” she added.

Moving forward, Culp said the next steps include collaborating with lead institutions on training, policies and procedures for implementing the SMART IRB Reliance Platform that can be used to support ethical review of multisite studies.

Addressing long-standing systemic challenges in multisite clinical trials, such as approval of a single protocol by multipleinstitutional review boards, will dramatically accelerate the delivery of new treatments to patients​,” said Culp.

Obtaining all CTSA Program hubs’ support for the SMART IRB authorization agreement isthe first milestone in a multi-step transformative initiative to provide a flexible platform that investigators can access nationwide to coordinate and streamline the ethics review process for their own multisite studies​.”

(Feature image: iStock/thamerpic)

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars